Senior insider sale
Chief Medical Officer at TRAVERE THERAPEUTICS, INC. — senior position signals high conviction
$2.94M
44.67K shares
What this filing means
INRIG JULA plans to sell 44.67K shares of TRAVERE THERAPEUTICS, INC. valued at approximately $2.94M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 9/15/2026ACC: 0001950047-26-009488
Officer· Chief Medical Officer
Since Jan 2022
44.67K
Shares to sell
$2.94M
Approx. market value
44.67K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months3
Exercise of Stock Options
Cash
9/15/2026
32.40KPerformance Stock Units
N/A
2/10/2025
4.62KRestricted Stock Units
N/A
1/1/2023
7.66KTotal acquired44.67K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
9/15/2026 | Exercise of Stock Options Cash | 32.40K | — |
2/10/2025 | Performance Stock Units N/A | 4.62K | — |
1/1/2023 | Restricted Stock Units N/A | 7.66K | — |
| Total | 44.67K | ||
Planned & Completed Dispositions1
NASDAQPlanned
Units to sell
44.67K
Market value
$2.94M
9/15/2026
Total
Units
44.67K
Value
$2.94M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
9/15/2026 | 44.67K | $2.94M | NASDAQ | Planned |
| Total | 44.67K | $2.94M | ||